Navigation Links
Xylitol reduces risk of cavities

daily intake of xylitol is recommended as a supplement for patients at high risk for tooth decay.
  • Xylitol products that actively stimulate the secretion of saliva should be the first choice, such as chewing gum.
  • About 6 g of xylitol per day is needed to counteract the production of acid and thereby reduce the risk of cavities.
  • The daily intake should be distributed over at least three occasions.
  • The products should contain as much xylitol as possible and not be mixed with other sweeteners.
    '"/>


    • Source:Swedish Research Council


    Page: 1 2

    Related biology news :

    1. Male circumcision reduces risk of HIV transmission from women to men
    2. Deficiency of growth hormone and IGF-1 reduces cancer and kidney disease, but creates other problems
    3. New miniaturised chip dramatically reduces time taken for DNA analysis
    4. New processing method reduces peanut allergenicity
    5. Blocking the nerve receptor EP1 in mouse models reduces brain damage caused by stroke
    6. Study finds that nutritionally enhanced rice reduces iron deficiency
    7. Overfishing in inland waters reduces biodiversity and threatens health
    8. Aspirin reduces cardiovascular risks in men and women -- but differently
    9. New gene reduces retinal degeneration in fruit flies
    10. Prenatal nicotine exposure reduces breathing response of newborns...
    11. Heat-shock protein vaccine reduces alveolar bone loss
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    		TAG: Xylitol reduces risk cavities

    Other Biology Technology:Ochsner and LSUHSC Partner to Provide Better Local Access to Comprehensive Cancer Care 2CEL-SCI's L.E.A.P.S. Technology Shows Potential to Treat Swine Influenza in Preclinical Studies 2CEL-SCI's L.E.A.P.S. Technology Shows Potential to Treat Swine Influenza in Preclinical Studies 3PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 2PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 3PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 4PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 5PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 6PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 7